Received Feb 4, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| MNP | MENINGOCOCCAL CONJUGATE (PENMENVY) | GLAXOSMITHKLINE BIOLOGICALS | 1 | 5S723 | LA |
Blistering at injection site; This non-serious case was reported by a physician via sales rep and described the occurrence of injection site blisters in a 16-year-old female patient who received Men ABCWY NVS (Penmenvy) (batch number 5S723, expiry date 08-OCT-2026) for prophylaxis. On 17-JAN-2026, the patient received the 1st dose of Penmenvy (left arm). On 19-JAN-2026, 2 days after receiving Penmenvy, the patient experienced injection site blisters (Verbatim: Blistering at injection site). On 22-JAN-2026, the outcome of the injection site blisters was resolved (duration 3 days). The reporter considered the injection site blisters to be related to Penmenvy. It was unknown if the reporter considered the injection site blisters to be related to Penmenvy Pre-Filled Syringe Device. The company considered the injection site blisters to be related to Penmenvy. It was unknown if the company considered the injection site blisters to be related to Penmenvy Pre-Filled Syringe Device. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK receipt date: 29-JAN-2026 The physician reported that blister broke and would resolve on its own.